Since anti-PD-1 antibodies bind to the suppressive receptor FcγRIIb, researchers have hypothesized that TAMs expressing a specific subset of the suppressive receptor FcγRIIb interact with the Fc domain of anti-PD-1 antibodies to undergo functional reprogramming, thereby acquiring enhanced tumor-promoting properties and ultimately inducing HPD. This evidence concerns the gene PDCD1 and neoplasm.